Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALOX5
REST API REST API
Homo sapiens
ALOX5 is differentially expressed in 304 experiments: 117 organism parts: bone marrow, cerebellum, ... (115 more);, 260 disease states: normal, control, ... (258 more);, 135 cell types 416 cell lines 32 compound treatments and 76 other conditions.
Synonyms 5-LOX
Orthologs F1MQ78_BOVIN (Bos taurus)   F6PID9_CIOIN (Ciona intestinalis)   F6UJG6_CIOIN (Ciona intestinalis)   ALOX5 (2 of 4) (Danio rerio)   ALOX5 (Gallus gallus)   ALOX5 (4 of 4) (Danio rerio)   ALOX5 (3 of 4) (Danio rerio)   ALOX5 (1 of 4) (Danio rerio)   Alox5 (Mus musculus)   ENSCING00000012298 (Ciona intestinalis)   F6Z015_CIOIN (Ciona intestinalis)   Alox5 (Rattus norvegicus)   alox5 (Xenopus laevis)   ALOX5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, oxidoreductase activity, leukotriene biosynthetic process, protein binding, iron ion binding, cytoplasm, membrane, metal ion binding, nuclear matrix, sensory perception of pain, sarcolemma, nuclear envelope lumen, soluble fraction, response to nutrient, oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen, nucleus, dendrite, nuclear envelope, nuclear membrane, lipoxygenase activity, arachidonate 5-lipoxygenase activity, leukotriene metabolic process, inflammatory response, acute inflammatory response, lipoxygenase pathway, leukotriene production involved in inflammatory response, response to hyperoxia, arachidonic acid metabolic process, positive regulation of vasoconstriction, oxidation-reduction process, prostanoid metabolic process
InterPro Term LipOase_LH2, LipOase_C, LipOase_mml
UniProt Accession B7ZLS0, P09917, E5FPY7
Gene-Disease Assocation ASTHMA, SUSCEPTIBILITY TO
Search EB-eye ENSG00000012779
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
WI38
2
E-MTAB-37, E-MTAB-62
HCC78
2
E-MTAB-62, E-GEOD-4342
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
PC3
2
E-GEOD-5258, E-MEXP-2034
410 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (59 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
3
E-AFMX-5, E-GEOD-6740, E-MTAB-25, E-TABM-145
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
fibroblast
2
E-GEOD-3920, E-GEOD-3204
129 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (71 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16728, E-GEOD-16363
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
acute promyelocytic leukemia
3
E-GEOD-96, E-MTAB-62, E-GEOD-1729
glioblastoma
1
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412, E-MEXP-567
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
254 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (22 experiments)

Factor Value U/D Experiments
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
control for EGF
1
E-GEOD-6462
placebo
1
E-MEXP-1327
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
26 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-2191, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532, E-MEXP-1901

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-17385, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-TABM-868, E-GEOD-20115, E-TABM-601, E-MEXP-1403, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-12773, E-MEXP-1446, E-GEOD-22278, E-MEXP-2146, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-19743, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-GEOD-2666

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-147

Processing time: 0.327 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM